GILD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Gilead Sciences Inc (GILD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and strategic acquisitions to enhance its drug pipeline provide a solid foundation for long-term growth. Despite the lack of immediate trading signals, the overall outlook supports a buy decision.
The MACD is below zero and negatively contracting, indicating a bearish trend. The RSI is at 21.456, suggesting the stock is nearing oversold territory. Moving averages are converging, showing no clear trend. The stock is trading near its S1 support level of 137.213, with resistance at 141.713.
Gilead's acquisition of Ouro Medicines for $2.18 billion to enhance its inflammation drug pipeline.
Positive financial performance with YoY revenue growth of 4.70%, net income growth of 22.43%, and EPS growth of 25.18%.
Strong analyst ratings with multiple price target increases and positive outlook on HIV franchise and long-acting therapies.
The MACD and RSI suggest a bearish short-term trend.
Barclays views the current valuation as 'rich,' which could limit immediate upside potential.
In Q4 2025, Gilead reported revenue of $7.93 billion (up 4.70% YoY), net income of $2.18 billion (up 22.43% YoY), and EPS of $1.74 (up 25.18% YoY). Gross margin improved slightly to 79.51%.
Analysts are generally positive on Gilead, with multiple firms raising price targets (ranging from $145 to $180) and highlighting strong performance in its HIV franchise and upcoming long-acting therapies. Jefferies and UBS emphasize Gilead's strong positioning in the biotech sector.
